SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer (SMCI) is trending after a preliminary business update revealed record order growth and a significant expansion in gross margins, sparking a massive rally and intense debate over potential short-squeeze dynamics. The community is sharply divided between bulls celebrating the margin recovery as a fundamental shift that justifies a higher valuation and skeptics who remain wary of management's history and the legitimacy of the order backlog.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR is trending as investors react to the potential launch of a Grayscale Near Trust, fueling speculation about increased institutional adoption. The community remains divided, with some highlighting the project's AI infrastructure and utility advancements, while others express caution regarding price volatility and the broader correction in the altcoin market.

X-Energy, Inc. operates as an energy company The firm focuses on modular nuclear reactors and fuel technology for clean energy generation. The company was founded by Kam Ghaffarian and Eben Mulder on 2009 and is headquartered in Rockville, MD.

X-Energy Inc. - Ordinary Shares- Class A

X-energy Inc

X-energy is trending as investors react to a federal initiative, backed by major tech firms like Microsoft and Nvidia, aimed at accelerating advanced nuclear reactors to support surging AI data center energy needs. Community discussion is heavily focused on the company's strategic positioning within this AI-driven energy sector, with many participants debating the long-term potential of small modular reactors versus the immediate regulatory and deployment challenges.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo is trending as investors react to a significant federal initiative, backed by major tech firms, aimed at accelerating advanced nuclear reactor development for AI data centers. While the community is actively debating the potential of these reactors to meet surging energy demands, sentiment remains polarized between long-term bulls encouraged by strategic government and institutional support and skeptics concerned about pre-revenue execution risks and recent price volatility.

Cybin, Inc. operates as a clinical-stage biopharmaceutical company on a mission to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. It is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Helus Pharma Inc.

Helus Pharma is trending due to the completion of enrollment in its Phase 3 APPROACH trial for HLP003 ahead of schedule, fueling retail optimism as the company approaches a key topline data readout later this year. The community remains intensely focused on the company's financial runway, the impact of recent leadership changes, and its potential as an acquisition target within the accelerating psychedelic and neuroplasticity-focused mental health sector.

NANO Nuclear Energy, Inc. is a microreactor and nuclear technology company, which provides supply energy services. Its products in technical development are ZEUS, a solid core battery reactor, and ODIN, a low-pressure coolant reactor. The company is founded by Jiang Yu in February, 2022 and is headquartered in New York, NY.

Nano Nuclear Energy Inc.

Nano Nuclear Energy is facing significant investor scrutiny as the stock experiences heavy volatility, with the community actively debating whether the company represents a high-risk long-term opportunity for AI power infrastructure or a speculative venture lacking current revenue. While some investors remain bullish on the sector's potential to bridge the U.S. power gap, others are expressing frustration over price declines and questioning the company's timeline for commercializing its microreactor technology.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors actively debate the potential for a broader market correction amid heightened geopolitical tensions in the Middle East and concerns over stretched valuations in the AI and semiconductor sectors. Community discussions are split between those utilizing the instrument as a tactical hedge against volatility and those cautioning about the risks of structural decay inherent in leveraged inverse ETFs.

Reddit, Inc. operates an entertainment, social networking, and news website where registered community members can submit content. The firm provides online news services where users can select and rank web content. It also offers a personalized filter on the day's story, using previous votes to determine what new things the user might like to read. The company was founded by Steven Ladd Huffman and Alexis Ohanian on June 23, 2005 and is headquartered in San Francisco, CA.

Reddit Inc. - Ordinary Shares - Class A

Reddit Inc

Reddit is trending as investors monitor technical chart patterns and shifting analyst sentiment regarding its AI-driven advertising potential. Meanwhile, the community is actively debating the company's valuation and volatility, with many traders closely watching for a potential breakout ahead of earnings.

Ginkgo Bioworks Holdings, Inc. engages in developing biological engineering products and custom microbes. Its platform enables biotechnology applications across diverse markets, from food, agriculture, industrial chemicals, and pharmaceuticals. It operates through the Cell Engineering and Biosecurity segments. The Cell Engineering segment includes end-to-end cell engineering solutions and cell engineering tools offerings for biological research and development. The Biosecurity segment focuses on biomonitoring and bioinformatics support services, offered to both government and non-government customers through its Canopy and Horizon offerings. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA.

Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A

Ginkgo Bioworks is gaining momentum following a partnership announcement with OpenAI to leverage AI-driven autonomous labs, which has community members buzzing about a potential shift in the company's long-term utility as biological infrastructure. While some investors remain skeptical due to past volatility and reverse-split history, others are closely tracking the stock's transition toward AI-integrated biomanufacturing and its potential as a strategic asset in domestic biotech initiatives.

ProShares Trust - ProShares UltraPro QQQ 3x Shares

ProShares UltraPro QQQ

TQQQ is seeing significant activity as investors react to fluctuating geopolitical tensions in the Middle East and ongoing rotation between semiconductor holdings and broader tech sectors. The community is closely monitoring institutional capex trends, end-of-quarter rebalancing, and the impact of potential rate policy shifts on AI-focused growth stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities

Breakthrough drugs, AI-powered technologies, and soaring global demand are driving one of healthcare’s fastest-growing markets   New York, NY – July 21, 2026 – Market News Updates News Commentary – Diabetes care is going through one of its biggest transformations in decades. Instead of simply helping patients keep their blood sugar under control, today’s therapies […]
The post Next-Generation Diabetes Therapies Are Reshaping Healthcare and Creating MultiBillion-Dollar Revenue Opportunities appeared first on Financial News Media.

Trump's first-term policies helped lower some insulin costs: HHS report

A new study from the Department of Health and Human Services shows that policies in President Donald Trump's first administration helped lower some patients' insulin costs below $35 for a 30-day supply.FOX Business obtained a copy of the new report set to be released as early as Monday. It shows...

Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings

Kalshi is expanding into biotech with contracts on FDA drug approvals from Sanofi and Gilead, as critics warn the wagers invite insider trading.read more...

Sanofi Wins FDA Approval for Wearable Injector Form of Blood Cancer Drug

FDA approves Sanofi's Sarclisa Escena, the first subcutaneous multiple myeloma treatment administered via a hands-free on-body injector.read more...

DNLI Stock Surges 59.4% Year to Date: Is There More Room for Growth?

Denali Therapeutics surges on Avlayah???s FDA approval, PRV sale and pipeline progress, but partnership changes and trial setbacks remain in focus.

R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy

R&D Change Underlines Sanofi SA (SNY) Prospects as One of the Best Dividend Stocks to Buy...

Snowflake Gains 6% in a Month: Should You Buy, Sell, or Hold the Stock?

SNOW's platform adoption and AI momentum are fueling gains, but rising competition, margin pressure, and premium valuation keep investors cautious.


KYMR Stock Soars 51% YTD on Progress of Atopic Dermatitis Drug

KYMR surges 51% year to date as KT-621 advances in atopic dermatitis and asthma, with pivotal data timelines accelerating and pipeline momentum building.

SNY's Nexviazyme Meets Goals in Infantile-Onset Pompe Disease Study

Sanofi's phase III Baby-COMET study meets all goals for Nexviazyme in infantile-onset Pompe disease, paving the way for a planned U.S. filing in H2 2026.

Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints

Sanofi says Nexviazyme met all Phase 3 trial endpoints in infantile Pompe disease, supporting a planned US label expansion filing in 2026.read more...

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

DNTH Stock Clocks Best Day In Over 3 Months On Strong Nerve Disorder Study Results

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	$1.09	--	--	N/A
Q1 '26	$1.04	$1.10	6.21%	BEAT
Q4 '25	$0.84	$0.91	8.38%	BEAT
Q3 '25	$1.58	$1.69	7.23%	BEAT
Q2 '25	$0.96	$0.91	-5.11%	MISSED

Feed

News

Sentiment

Earnings

Fundamentals

Info

SNYSanofi-Aventis

Upcoming Earnings: Q2 '26

Historical Earnings

Latest SNY News